Castle Biosciences, Inc. Common Stock CSTL
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $44.33 (+24.0% upside)
Key Stats
- Today's Range
- $35.49 – $36.54
- 50-Day Range
- $22.46 – $36.85
- 52-Week Range
- $17.72 – $44.28
- Volume
- 93K shs
- Average Volume
- 333K shs
- Market Cap
- $1.12 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.39
- Price / Sales
- 3.14
Short Interest
- Short Interest
- 0.04%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $357.28 million
- Net Income
- $-19,415,000
- Net Margin
- -5.43%
- Return on Equity
- -4.13%
- Debt-to-Equity
- 0.02
About Castle Biosciences, Inc. Common Stock
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Related Stocks
Compare head-to-head: CSTL vs NTRA·CSTL vs DGX·CSTL vs CAI·CSTL vs BLLN
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.